HPV Associated Head and Neck Cancer
AbstractHead and neck cancers (HNCs) are a highly heterogeneous group of tumours that are associated with diverse clinical outcomes. Recent evidence has demonstrated that human papillomavirus (HPV) is involved in up to 25% of HNCs; particularly in the oropharyngeal carcinoma (OPC) subtype where it can account for up to 60% of such cases. HPVs are double-stranded DNA viruses that infect epithelial cells; numerous HPV subtypes, including 16, 18, 31, 33, and 35, drive epithelial cell transformation and tumourigenesis. HPV positive (HPV+) HNC represents a distinct molecular and clinical entity from HPV negative (HPV−) disease; the biological basis for which remains to be fully elucidated. HPV positivity is strongly correlated with a significantly superior outcome; indicating that such tumours should have a distinct management approach. This review focuses on the recent scientific and clinical investigation of HPV+ HNC. In particular, we discuss the importance of molecular and clinical evidence for defining the role of HPV in HNC, and the clinical impact of HPV status as a biomarker for HNC. View Full-Text
Share & Cite This Article
Spence, T.; Bruce, J.; Yip, K.W.; Liu, F.-F. HPV Associated Head and Neck Cancer. Cancers 2016, 8, 75.
Spence T, Bruce J, Yip KW, Liu F-F. HPV Associated Head and Neck Cancer. Cancers. 2016; 8(8):75.Chicago/Turabian Style
Spence, Tara; Bruce, Jeff; Yip, Kenneth W.; Liu, Fei-Fei. 2016. "HPV Associated Head and Neck Cancer." Cancers 8, no. 8: 75.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.